<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04928183</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00096251</org_study_id>
    <nct_id>NCT04928183</nct_id>
  </id_info>
  <brief_title>The Impact of Carbon Monoxide and Altitude on Vascular Function</brief_title>
  <acronym>CarMA</acronym>
  <official_title>The Impact of Carbon Monoxide and Altitude on Vascular Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CarMA (Carbon Monoxide and Altitude) Study aims to observe the vascular effects of carbon&#xD;
      monoxide exposure at low and high altitudes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each year, millions of people make journeys from low altitude regions to high altitude for&#xD;
      recreation, travel, and religious pilgrimage. Carbon monoxide (CO) is commonly associated&#xD;
      with cigarette smoke, exhaust fumes, and is viewed as a life-threatening toxic gas. Exposure&#xD;
      to CO occurs during travel to and during activities common in high-altitude travel and&#xD;
      pilgrimage including vehicle fumes, incense, and second-hand smoke exposure. High altitude&#xD;
      exposure and CO exposure have been observed independently to have complex and opposing&#xD;
      effects on vascular endothelial function. Observation of these stimuli together in a&#xD;
      controlled environment may allow for further understanding of the underlying mechanisms of&#xD;
      vascular physiology and adaptations to both high-altitude and CO exposure. The CarMA (Carbon&#xD;
      Monoxide and Altitude) Study aims to observe the vascular effects of carbon monoxide exposure&#xD;
      at low and high altitudes. Recently, other studies have showed a significant improvement in&#xD;
      flow mediated dilation (FMD) with acute exposure to low levels of CO To date, no research has&#xD;
      been presented concerning the effect of CO on vascular function at altitude. The present&#xD;
      study aims to observe the effect of acute carbon monoxide exposure on 1) flow mediated&#xD;
      dilation, 2) conduit artery flow in exercise induced reactive hyperemia at sea level and at&#xD;
      altitude, and 3) the effect of CO on vascular function in a high altitude dwelling (sherpa)&#xD;
      population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 10, 2021</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Participants will partake in both room air and CO exposure on 2 separate visits.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participant will not be aware of which rebreathe treatment (CO or Room Air) they are receiving.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Flow mediated dilation (FMD)</measure>
    <time_frame>15 minutes</time_frame>
    <description>Change in brachial artery diameter (assessed via ultrasound) following release of arterial occlusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exercise induced hyperemia</measure>
    <time_frame>15 minutes</time_frame>
    <description>Blood flow within the brachial artery during rhythmic handgrip exercise.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phenylephrine sensitivity</measure>
    <time_frame>5 min</time_frame>
    <description>Change in brachial artery conductance following an infusion of phenylephrine</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Vasodilation</condition>
  <condition>Vasoconstriction</condition>
  <arm_group>
    <arm_group_label>Room Air Rebreathe</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Rebreathe protocol will be completed with a room air syringe rather than CO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CO Rebreathe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rebreathe protocol will be completed with Carbon Monoxide</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Carbon monoxide rebreathe</intervention_name>
    <description>Carbon monoxide exposure to increase blood (Carboxyhemoglobin) COHb safely to ~10%</description>
    <arm_group_label>CO Rebreathe</arm_group_label>
    <other_name>Schmidt-Prommer blood volume test</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Nitroprusside</intervention_name>
    <description>Bolus Sodium Nitroprusside (SNP) injection for endothelium-independent vasodilation measure</description>
    <arm_group_label>CO Rebreathe</arm_group_label>
    <arm_group_label>Room Air Rebreathe</arm_group_label>
    <other_name>Nipride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine Hydrochloride</intervention_name>
    <description>Bolus Phenylephrine injection for observe Î±1-mediated vasoconstriction during mild exercise</description>
    <arm_group_label>CO Rebreathe</arm_group_label>
    <arm_group_label>Room Air Rebreathe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between the ages of 18-50 years&#xD;
&#xD;
          -  No medical history of cardiovascular, respiratory, nervous system, or metabolic&#xD;
             disease.&#xD;
&#xD;
          -  Women must be pre-menopausal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with any known cardiovascular, respiratory, nervous system, or metabolic&#xD;
             disease.&#xD;
&#xD;
          -  Having travelled above 2,000m within 1 month of testing at low and high altitude.&#xD;
&#xD;
          -  Women who are pregnant, confirmed by a pregnancy test.&#xD;
&#xD;
          -  Women who are post-menopausal.&#xD;
&#xD;
          -  Participants that are classified as obese (body mass index &gt; 30 kg/m2).&#xD;
&#xD;
          -  Participants who are current daily smokers.&#xD;
&#xD;
          -  Participants that are currently taking monoamine (MAO) inhibitors, or tricyclic&#xD;
             antidepressants.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean van Diepen, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Craig Steinback, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicholas Cheung, BSc</last_name>
    <phone>(780) 492-5553</phone>
    <email>nkcheung@ualberta.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Scott Thrall</last_name>
    <email>sthrall@ualberta.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2R3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Steinback, PhD</last_name>
      <phone>(780) 492-5553</phone>
      <email>craig.steinback@ualberta.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Basnyat B. High altitude pilgrimage medicine. High Alt Med Biol. 2014 Dec;15(4):434-9. doi: 10.1089/ham.2014.1088. Review.</citation>
    <PMID>25330393</PMID>
  </reference>
  <reference>
    <citation>Rezk-Hanna M, Mosenifar Z, Benowitz NL, Rader F, Rashid M, Davoren K, Moy NB, Doering L, Robbins W, Sarna L, Li N, Chang LC, Elashoff RM, Victor RG. High Carbon Monoxide Levels from Charcoal Combustion Mask Acute Endothelial Dysfunction Induced by Hookah (Waterpipe) Smoking in Young Adults. Circulation. 2019 May 7;139(19):2215-2224. doi: 10.1161/CIRCULATIONAHA.118.037375.</citation>
    <PMID>30764644</PMID>
  </reference>
  <reference>
    <citation>Choi BG, Lee J, Kim SW, Lee MW, Baek MJ, Ryu YG, Choi SY, Byun JK, Mashaly A, Park Y, Jang WY, Kim W, Choi JY, Park EJ, Na JO, Choi CU, Lim HE, Kim EJ, Park CG, Seo HS, Oh DJ, Rha SW. The association of chronic air pollutants with coronary artery spasm, vasospastic angina, and endothelial dysfunction. Coron Artery Dis. 2018 Jun;29(4):336-343. doi: 10.1097/MCA.0000000000000603.</citation>
    <PMID>29334505</PMID>
  </reference>
  <reference>
    <citation>Weber LP, Al-Dissi A, Marit JS, German TN, Terletski SD. Role of carbon monoxide in impaired endothelial function mediated by acute second-hand tobacco, incense, and candle smoke exposures. Environ Toxicol Pharmacol. 2011 May;31(3):453-9. doi: 10.1016/j.etap.2011.02.008. Epub 2011 Feb 26.</citation>
    <PMID>21787716</PMID>
  </reference>
  <reference>
    <citation>Tymko MM, Tremblay JC, Bailey DM, Green DJ, Ainslie PN. The impact of hypoxaemia on vascular function in lowlanders and high altitude indigenous populations. J Physiol. 2019 Dec;597(24):5759-5776. doi: 10.1113/JP277191. Epub 2019 Nov 28. Review.</citation>
    <PMID>31677355</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>June 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroprusside</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Carbon Monoxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

